Paradigm Biopharmaceuticals Limited

CHIA:PAR Stock Report

Market Cap: AU$131.0m

Paradigm Biopharmaceuticals Management

Management criteria checks 3/4

Paradigm Biopharmaceuticals' CEO is Paul Rennie, appointed in Jan 2014, has a tenure of 10.92 years. total yearly compensation is A$1.10M, comprised of 86.5% salary and 13.5% bonuses, including company stock and options. directly owns 2.67% of the company’s shares, worth A$3.50M. The average tenure of the management team and the board of directors is 4.3 years and 4 years respectively.

Key information

Paul Rennie

Chief executive officer

AU$1.1m

Total compensation

CEO salary percentage86.5%
CEO tenure10.9yrs
CEO ownership2.7%
Management average tenure4.3yrs
Board average tenure4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Rennie's remuneration changed compared to Paradigm Biopharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$1mAU$948k

-AU$59m

Mar 31 2024n/an/a

-AU$64m

Dec 31 2023n/an/a

-AU$69m

Sep 30 2023n/an/a

-AU$60m

Jun 30 2023AU$2mAU$602k

-AU$52m

Mar 31 2023n/an/a

-AU$48m

Dec 31 2022n/an/a

-AU$44m

Sep 30 2022n/an/a

-AU$42m

Jun 30 2022AU$1mAU$219k

-AU$39m

Mar 31 2022n/an/a

-AU$40m

Dec 31 2021n/an/a

-AU$41m

Sep 30 2021n/an/a

-AU$37m

Jun 30 2021AU$1mAU$510k

-AU$34m

Mar 31 2021n/an/a

-AU$31m

Dec 31 2020n/an/a

-AU$28m

Sep 30 2020n/an/a

-AU$20m

Jun 30 2020AU$632kAU$462k

-AU$12m

Mar 31 2020n/an/a

-AU$14m

Dec 31 2019n/an/a

-AU$16m

Sep 30 2019n/an/a

-AU$16m

Jun 30 2019AU$1mAU$420k

-AU$16m

Mar 31 2019n/an/a

-AU$11m

Dec 31 2018n/an/a

-AU$7m

Sep 30 2018n/an/a

-AU$7m

Jun 30 2018AU$573kAU$380k

-AU$6m

Compensation vs Market: Paul's total compensation ($USD685.65K) is above average for companies of similar size in the Australian market ($USD291.73K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Rennie (65 yo)

10.9yrs

Tenure

AU$1,096,287

Compensation

Mr. Paul John Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, served as Independent Non-Executive Chairman at NeuroScientific Biopharmaceuticals Limited since June 21, 2021 until November 23, 2022, was it...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Rennie
Founder10.9yrsAU$1.10m2.67%
A$ 3.5m
Donna Skerrett
Chief Medical Officer2.4yrsAU$1.23m0.31%
A$ 410.4k
Abby Macnish Niven
Company Secretary & CFO2.3yrsno datano data
Ravi Krishnan
Chief Scientific Officer9.3yrsno datano data
Simon White
Director of Investor Relationsno datano datano data
Michael Imperiale
Global Head of Drug Safety & MPS4.5yrsno datano data
Beverley Huttmann
Commercial Head4.2yrsno datano data
Michelle Coffey
Global Head of Regulatory Affairsno datano datano data
Mukesh Ahuja
Global Clinical Head of OAno datano datano data

4.3yrs

Average Tenure

Experienced Management: PAR's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Rennie
Founder10.6yrsAU$1.10m2.67%
A$ 3.5m
Amos Meltzer
Independent & Non-Executive Director4yrsAU$88.80kno data
Matthew Fry
Independent Non-Executive Directorless than a yearAU$24.24k0.41%
A$ 532.4k

4.0yrs

Average Tenure

Experienced Board: PAR's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 15:04
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Paradigm Biopharmaceuticals Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Soo RomanoffEdison Investment Research
Arron AatkarEdison Investment Research